Exploring the promising potential of GLP-1 and GIP/GLP-1 receptor agonists in treating respiratory disorders like asthma, COPD, and COVID-19 outcomes.
Exploring how SGLT2 inhibitors, originally designed for diabetes, are now revolutionizing heart and kidney medicine through unexpected mechanisms.